Sarafloxacin-d8 is intended for use as an internal standard for the quantification of sarafloxacin by GC- or LC-MS. Sarafloxacin is a fluoroquinolone antibiotic.1,2 It is active against various clinical isolates of bacteria, including Bacteroides, Fusobacterium, Eubacterium, Actinomyces, and Peptococcus (MICs = 0.5-2 µg/ml).1 Sarafloxacin inhibits P. aeruginosa DNA gyrase.3 It decreases air sac lesion severity in a chick model of E. coli-induced colisepticemia when administered at a dose of 8 mg/kg in the drinking water 24 hours per day for five days.2 Formulations containing sarafloxacin have previously been used in the treatment of bacterial infections in poultry.
1.Bansal, M.B., and Thadepalli, H.Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitroAntimicrob. Agents Chemother.31(4)619-621(1987) 2.Charleston, B., Gate, J.J., Aitken, I.A., et al.Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickensAntimicrob. Agents Chemother.42(1)83-87(1998) 3.Moir, D.T., Di, M., Opperman, T., et al.A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agentsJ. Biomol. Screen.12(6)855-864(2007)